Apellis Pharmaceuticals (NASDAQ:APLS) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw strong trading volume on Wednesday . 10,390,190 shares changed hands during mid-day trading, an increase of 146% from the previous session’s volume of 4,226,844 shares.The stock last traded at $40.3950 and had previously closed at $40.23.

Apellis Pharmaceuticals News Summary

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Biogen acquisition: a definitive agreement values Apellis at about $5.6B, gives Apellis shareholders $41 in cash plus a CVR tied to SYFOVRE sales — a clear near-term exit and takeover premium that explains the stock spike. Biogen to buy Apellis Pharmaceuticals for $5.6 billion
• Positive Sentiment: Market reaction: shares traded on much heavier-than-normal volume and jumped sharply following the announcement, reflecting immediate arbitrage interest and takeover premium realization. Apellis Pharmaceuticals (APLS) Moves 135.4% Higher
• Neutral Sentiment: Analysts mostly maintain neutral/market-perform stances with price targets clustered near the deal price (~$41), indicating limited analyst upside beyond the transaction but consensus acceptance of the bid. Analyst coverage notes
• Negative Sentiment: Shareholder investigations: multiple law firms (Kahn Swick & Foti, Ademi, Halper Sadeh) have opened probes into whether the sale price and process are fair to Apellis shareholders — potential legal/closing risk and added scrutiny on deal terms. Investor Alert: Kahn Swick & Foti Investigates Sale
• Negative Sentiment: Analyst downgrades and target cuts: some firms have trimmed price targets or downgraded the stock (e.g., Needham downgrade, Cantor Fitzgerald target cuts), reflecting differing views on standalone upside and/or model updates ahead of the deal. These actions can pressure sentiment if deal terms change. Cantor Fitzgerald Cuts PT on Apellis

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on APLS shares. Wells Fargo & Company dropped their price target on shares of Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 20th. Citigroup restated a “neutral” rating and issued a $41.00 target price (down from $44.00) on shares of Apellis Pharmaceuticals in a report on Wednesday. Stifel Nicolaus cut their price target on shares of Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, December 19th. The Goldman Sachs Group reissued a “sell” rating and issued a $19.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 29th. Nine analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $31.89.

Apellis Pharmaceuticals Stock Performance

The company has a quick ratio of 2.70, a current ratio of 3.14 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $5.16 billion, a P/E ratio of 310.75 and a beta of 0.26. The company’s 50 day moving average is $21.11 and its 200-day moving average is $22.58.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The firm had revenue of $199.91 million during the quarter, compared to the consensus estimate of $199.28 million. During the same period in the previous year, the firm posted ($0.29) earnings per share. The business’s revenue was down 5.9% compared to the same quarter last year. As a group, equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insiders Place Their Bets

In related news, insider Caroline Baumal sold 2,797 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $60,890.69. Following the completion of the sale, the insider directly owned 86,527 shares of the company’s stock, valued at $1,883,692.79. The trade was a 3.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Pascal Deschatelets sold 5,928 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $129,052.56. Following the completion of the transaction, the insider owned 1,151,382 shares in the company, valued at approximately $25,065,586.14. The trade was a 0.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 115,537 shares of company stock worth $2,486,082 over the last three months. Insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Jones Financial Companies Lllp raised its holdings in Apellis Pharmaceuticals by 206.8% during the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after buying an additional 1,373 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Apellis Pharmaceuticals by 141.2% in the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after acquiring an additional 1,570 shares during the last quarter. Allworth Financial LP lifted its position in Apellis Pharmaceuticals by 64.1% in the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after acquiring an additional 857 shares in the last quarter. Quantbot Technologies LP bought a new stake in Apellis Pharmaceuticals during the 3rd quarter worth approximately $64,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Apellis Pharmaceuticals by 338.5% in the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after purchasing an additional 4,191 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.